MA46356B1 - Inhibiteurs de bêta-lactamases - Google Patents

Inhibiteurs de bêta-lactamases

Info

Publication number
MA46356B1
MA46356B1 MA46356A MA46356A MA46356B1 MA 46356 B1 MA46356 B1 MA 46356B1 MA 46356 A MA46356 A MA 46356A MA 46356 A MA46356 A MA 46356A MA 46356 B1 MA46356 B1 MA 46356B1
Authority
MA
Morocco
Prior art keywords
beta
lactamase inhibitors
compounds
relates
gram
Prior art date
Application number
MA46356A
Other languages
English (en)
Inventor
Robert Lowell Simmons
Anthony Casarez
Xiaodong Lin
Folkert Reck
Qingming Zhu
Markus Furegati
Guido Koch
Flavio Ossola
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA46356B1 publication Critical patent/MA46356B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

La présente invention concerne de manière générale des composés de formule (a), tels que décrits ici, qui agissent en tant qu'inhibiteurs de bêta-lactamase, et des sels, des formes cristallines et des formulations de ceux-ci. Dans certains aspects, l'invention concerne des procédés d'utilisation de tels composés en combinaison avec un antibiotique bêta-lactame pour traiter des infections provoquées par des bactéries à gram négatif, y compris des souches résistantes aux médicaments.
MA46356A 2016-09-28 2017-09-28 Inhibiteurs de bêta-lactamases MA46356B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662401022P 2016-09-28 2016-09-28
PCT/IB2017/055973 WO2018060926A1 (fr) 2016-09-28 2017-09-28 Inhibiteurs de bêta-lactamases

Publications (1)

Publication Number Publication Date
MA46356B1 true MA46356B1 (fr) 2020-08-31

Family

ID=60191429

Family Applications (2)

Application Number Title Priority Date Filing Date
MA050427A MA50427A (fr) 2016-09-28 2017-09-28 Combinaison pharmaceutique entre un inhibiteur tricyclique de bêta-lactamase et des antibiotiques spécifiques de bêta-lactamase
MA46356A MA46356B1 (fr) 2016-09-28 2017-09-28 Inhibiteurs de bêta-lactamases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA050427A MA50427A (fr) 2016-09-28 2017-09-28 Combinaison pharmaceutique entre un inhibiteur tricyclique de bêta-lactamase et des antibiotiques spécifiques de bêta-lactamase

Country Status (42)

Country Link
US (2) US10597396B2 (fr)
EP (2) EP3698796B1 (fr)
JP (1) JP7094275B2 (fr)
KR (1) KR20190058492A (fr)
CN (1) CN109843894B (fr)
AR (1) AR109737A1 (fr)
AU (1) AU2017335405B2 (fr)
BR (1) BR112019002195A2 (fr)
CA (1) CA3030373A1 (fr)
CL (1) CL2019000232A1 (fr)
CO (1) CO2019001995A2 (fr)
CR (1) CR20190104A (fr)
CU (1) CU24562B1 (fr)
CY (1) CY1123062T1 (fr)
DK (1) DK3519419T3 (fr)
EA (1) EA036675B1 (fr)
EC (1) ECSP19016602A (fr)
ES (2) ES2801874T3 (fr)
HR (1) HRP20200986T1 (fr)
HU (1) HUE049788T2 (fr)
IL (1) IL265626B (fr)
JO (1) JOP20190061A1 (fr)
LT (1) LT3519419T (fr)
MA (2) MA50427A (fr)
MD (1) MD3519419T2 (fr)
ME (1) ME03735B (fr)
MX (1) MX380076B (fr)
MY (1) MY189632A (fr)
PE (1) PE20190459A1 (fr)
PH (1) PH12019500331A1 (fr)
PL (1) PL3519419T3 (fr)
PT (1) PT3519419T (fr)
RS (1) RS60483B1 (fr)
SG (1) SG11201900394SA (fr)
SI (1) SI3519419T1 (fr)
SM (1) SMT202000343T1 (fr)
TN (1) TN2019000020A1 (fr)
TW (1) TWI746652B (fr)
UA (1) UA123833C2 (fr)
UY (1) UY37424A (fr)
WO (1) WO2018060926A1 (fr)
ZA (1) ZA201900137B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN119707784A (zh) 2018-09-21 2025-03-28 株式会社Api 氨基酸衍生物的制备方法
AU2021473165B2 (en) * 2021-11-09 2025-05-22 Guangzhou HC New Drug Research Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING β-LACTAM COMPOUND AND USE THEREOF
CN115368261A (zh) * 2022-07-29 2022-11-22 武汉理工大学 N-烯丙基-n-苄基-2-(苄基氨基)乙酰胺的合成方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0090505B1 (fr) 1982-03-03 1990-08-08 Genentech, Inc. Antithrombine III humaine, séquences d'ADN pour celli-ci, vecteurs de clonage et d'expression contenant ces sequences et cultures de cellules transformées par ceux-ci, procédé pour exprimer l'antithrombine III humaine et compositions pharmaceutiques la contenant
CA2143519A1 (fr) * 1994-03-11 1995-09-12 F. Hoffmann-La Roche Ag Beta-lactames
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
ES2308787T3 (es) 1996-08-16 2008-12-01 Schering Corporation Antigenos de superficie de celular de mamiferos; reactivos relacionados.
JP2001520039A (ja) 1997-10-21 2001-10-30 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒト腫瘍壊死因子レセプター様タンパク質、ｔｒ１１，ｔｒ１１ｓｖ１およびｔｒ１１ｓｖ２
AU2591599A (en) 1998-02-09 1999-08-23 Genentech Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
WO2001003720A2 (fr) 1999-07-12 2001-01-18 Genentech, Inc. Stimulation ou inhibition de l'angiogenese et de la cardiovascularisation avec des homologues de ligands et de recepteurs du facteur de necrose tumorale
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
US7618632B2 (en) 2003-05-23 2009-11-17 Wyeth Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
WO2005007190A1 (fr) 2003-07-11 2005-01-27 Schering Corporation Agonistes ou antagonistes du recepteur du facteur de necrose tumorale induit par les glucocorticoides (gitr) ou de son ligand utilises dans le traitement des troubles immuns, des infections et du cancer
WO2005055808A2 (fr) 2003-12-02 2005-06-23 Genzyme Corporation Compositions et methodes pour le diagnostic et le traitement du cancer du poumon
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
US20060002932A1 (en) 2004-06-04 2006-01-05 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
WO2007133822A1 (fr) 2006-01-19 2007-11-22 Genzyme Corporation Anticorps anti-gitr destinés au traitement du cancer
AU2007300531A1 (en) 2006-09-27 2008-04-03 Merck Sharp & Dohme Corp. Novel inhibitors of beta-lactamase
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
ES2533826T3 (es) * 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
NZ590667A (en) 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
CN102149820B (zh) 2008-09-12 2014-07-23 国立大学法人三重大学 能够表达外源gitr配体的细胞
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
EP3255060A1 (fr) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
US20120053350A1 (en) 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
WO2011066342A2 (fr) 2009-11-24 2011-06-03 Amplimmune, Inc. Inhibition simultanée de pd-l1/pd-l2
CA2785907A1 (fr) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Produits de recombinaison de liaison a ron et leurs procedes d'utilisation
MX340533B (es) * 2011-08-30 2016-07-13 Wockhardt Ltd Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
EP3052497B1 (fr) 2011-09-13 2017-06-28 Wockhardt Limited Composés contenant de l'azote et leur utilisation
WO2013039954A1 (fr) 2011-09-14 2013-03-21 Sanofi Anticorps anti-gitr
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9025112B2 (en) 2012-02-02 2015-05-05 Apple Inc. Display with color mixing prevention structures
EP2814483A2 (fr) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Méthodes de traitement d'infections bactériennes
KR20150003777A (ko) 2012-03-30 2015-01-09 큐비스트 파마슈티컬즈 인코포레이티드 이속사졸 β-락타마제 억제제
TW201343645A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
BR112015003592B1 (pt) 2012-08-25 2020-04-14 Wockhardt Ltd derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
WO2014141132A1 (fr) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. Nouveaux composés hétérocycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de β-lactamase
US9434728B1 (en) * 2013-10-11 2016-09-06 Wockhardt Limited Nitrogen containing compounds and their use
WO2016116788A1 (fr) * 2015-01-24 2016-07-28 Wockhardt Limited Composés bicycliques contenant de l'azote et leur utilisation dans le traitement d'infections bactériennes
CN107438614B (zh) * 2015-04-03 2020-01-31 拜欧蒂姆公司 杂环化合物及它们在预防或治疗细菌感染中的应用
EP3075381A1 (fr) * 2015-04-03 2016-10-05 Mutabilis Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز

Also Published As

Publication number Publication date
ZA201900137B (en) 2019-09-25
CU24562B1 (es) 2022-01-13
EP3519419B1 (fr) 2020-05-27
US10065957B2 (en) 2018-09-04
BR112019002195A2 (pt) 2019-05-14
CN109843894B (zh) 2022-02-08
CO2019001995A2 (es) 2019-03-08
JP7094275B2 (ja) 2022-07-01
PE20190459A1 (es) 2019-04-01
US20190177324A1 (en) 2019-06-13
UY37424A (es) 2018-04-30
EA201990819A1 (ru) 2019-08-30
AU2017335405A1 (en) 2019-01-31
JOP20190061A1 (ar) 2019-03-26
SMT202000343T1 (it) 2020-07-08
SG11201900394SA (en) 2019-04-29
LT3519419T (lt) 2020-09-10
ES2801874T3 (es) 2021-01-14
HUE049788T2 (hu) 2020-10-28
CY1123062T1 (el) 2021-10-29
WO2018060926A1 (fr) 2018-04-05
CN109843894A (zh) 2019-06-04
HRP20200986T1 (hr) 2020-10-16
EP3698796B1 (fr) 2021-10-27
CU20190016A7 (es) 2019-10-04
AU2017335405B2 (en) 2021-08-12
AR109737A1 (es) 2019-01-16
MD3519419T2 (ro) 2020-08-31
US20180086762A1 (en) 2018-03-29
ECSP19016602A (es) 2019-03-29
TW201817730A (zh) 2018-05-16
CR20190104A (es) 2019-05-02
PT3519419T (pt) 2020-06-26
EP3698796A1 (fr) 2020-08-26
ME03735B (fr) 2021-01-20
MX380076B (es) 2025-03-11
IL265626A (en) 2019-05-30
SI3519419T1 (sl) 2020-09-30
CA3030373A1 (fr) 2018-04-05
DK3519419T3 (da) 2020-06-29
MY189632A (en) 2022-02-22
IL265626B (en) 2021-08-31
MX2019003640A (es) 2019-08-12
US10597396B2 (en) 2020-03-24
PL3519419T3 (pl) 2020-11-02
TWI746652B (zh) 2021-11-21
UA123833C2 (uk) 2021-06-09
TN2019000020A1 (en) 2020-07-15
MA50427A (fr) 2021-05-12
EP3519419A1 (fr) 2019-08-07
JP2019529469A (ja) 2019-10-17
PH12019500331A1 (en) 2019-08-05
CL2019000232A1 (es) 2019-05-10
RS60483B1 (sr) 2020-08-31
KR20190058492A (ko) 2019-05-29
ES2902579T3 (es) 2022-03-29
EA036675B1 (ru) 2020-12-07

Similar Documents

Publication Publication Date Title
MA37383A1 (fr) Compose heterobicycliques comme inhibiteurs de la beta lactamase
MA39777B1 (fr) Composes organiques de la famille des monobactams pour le traitement d'infections bactériennes
MA42292B1 (fr) Dérivés de sulfamoylarylamide cyclisés et leur utilisation à titre de médicaments pour le traitement de l'hépatite b
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
BR112013032770A2 (pt) composições farmacêuticas compreendendo antibiótico beta-lactama, sulbactama e inibidor de beta-lactamase
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MX385507B (es) Compuestos inhibidores de beta-lactamasa
MA46356B1 (fr) Inhibiteurs de bêta-lactamases
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
MA45920A (fr) Inhibiteurs de pyridopyrimidinone cdk2/4/6
MA38922A2 (fr) Dérivés de quinolizine substitués utiles en tant qu'inhibiteurs de l'integrase du vih
MA42244B1 (fr) Dérivés de 3-tétrazolyl-benzène-1,2-disulfonamide en tant qu'inhibiteurs de métallo-bêta-lactamase
MA39995B1 (fr) Composés destinés à traiter l'amyotrophie spinale
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA40254B1 (fr) Polymorphes du selinexor
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA54386B1 (fr) Modulateurs de trex1
MA56674B1 (fr) Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle